Lilly MDR-TB Partnership

Lilly: Announcing the 2015 REACH Lilly MDR TB Partnership Media Award Winners

Blog

Today’s guest blog comes from Sunita Prasad, senior manager for Lilly’s MDR-TB Partnership in India.

Tuberculosis (TB) continues to pose a monumental global health challenge. The disease affected nine million people in 2013, and claimed 1.5 million lives. In India, 1,000 people die of TB daily, though the disease is fully curable.

Lilly: Forging Alliances is Crucial to Fighting Tuberculosis

Blog

Today’s guest Blogger is Dr. Lasha Goguadze, Senior Health Officer, Global Tuberculosis Programme, International Federation of the Red Cross and Red Crescent Societies. He is based in Geneva.

Lilly: Drug-Resistant TB Demands More R&D

Blog

Today's guest blog comes from Lilly's vice president of Global Health Programs, Evan Lee, M.D. 

A new article published by a team from the World Health Organization in the European Respiratory Journal shows that while we’re seeing gradual expansion in care for multidrug-resistant TB (MDR-TB), there continues to be an urgent need to accelerate the scale up of diagnosis and treatment efforts in heavily affected countries. 

Lilly: Taking the Fight to MDR-TB

Blog

Today's guest blog comes from Lilly's vice president of Global Health Programs, Evan Lee, M.D.

“Americans can no longer afford to be indifferent to the rise of drug-resistant tuberculosis.”

Lilly: Union Conference on Lung Health

Blog
Today's guest blog comes from Lilly's vice president of Global Health Programs, Evan Lee, M.D.
 
Let’s start with two questions today:
 
What deadly infectious disease continues to kill up to 1.5 million people each year and continues to mutate and evolve into forms that are increasingly hard to treat?  And especially impacts countries with weak health systems? No, it’s not what you’re thinking! I’m talking about tuberculosis and the continued increase in the number of people suffering from drug-resistant TB.
 

Lilly: Seeking Solutions to a Global MDR-TB Crisis

Blog
Over a decade ago, we committed ourselves to the global fight against multi-drug resistant tuberculosis (MDR-TB). Today, a new report out from the Lilly MDR-TB Partnership shares insights from a core component of the partnership: the technology transfer program.

Lilly: Chinese and Russian Experts Exchange MDR-TB Best Practices

Blog
 
Today’s guest blog comes from Mikhail Volik and Zhi Jun He, Lilly MDR-TB program officers in Russia and China, respectively.
 

Lilly: Spreading Knowledge to Stop TB in India

Blog

Today’s guest blog comes from Sunita Prasad, senior manager for Lilly’s MDR-TB programs in India.
 

Lilly: A Good Start to Ending TB in China

Blog
 
Today’s guest blog comes from He Zhijun, Lilly’s CSR Manager and Program Officer for the Lilly MDR-TB Partnership in China.
 
In late June, I organized our first media visit to the Heilongjiang Provincial Infectious Disease Hospital located in Harbin, the provincial capital of China’s Heilongjiang province. The hospital is one of six pilot centers from the Lilly-China Medical Association TB Society collaboration focused on enhancing clinical skills of tuberculosis (TB) physicians.
 

Lilly: Moving Beyond Training to Fight MDR-TB

By David Marbaugh
Blog

Today's guest blog comes from Lilly's Vice President of Global Health Programs and Access, Dr. Evan Lee.

Indian health officials continue to grapple with the rise of multidrug-resistant tuberculosis (MDR-TB). The latest data show a marked increase in the number of drug-resistant cases over the past year in Mumbai, India’s most populous city. More than 600 additional people with MDR-TB were put on treatment in 2013 compared to 2012.

Pages

Subscribe to Lilly MDR-TB Partnership